LLY

751.96

-3.18%↓

JNJ

155.56

-1.06%↓

UNH

385.73

-1.37%↓

ABBV

185.44

-1.29%↓

ABT

133.82

-0.01%↓

LLY

751.96

-3.18%↓

JNJ

155.56

-1.06%↓

UNH

385.73

-1.37%↓

ABBV

185.44

-1.29%↓

ABT

133.82

-0.01%↓

LLY

751.96

-3.18%↓

JNJ

155.56

-1.06%↓

UNH

385.73

-1.37%↓

ABBV

185.44

-1.29%↓

ABT

133.82

-0.01%↓

LLY

751.96

-3.18%↓

JNJ

155.56

-1.06%↓

UNH

385.73

-1.37%↓

ABBV

185.44

-1.29%↓

ABT

133.82

-0.01%↓

LLY

751.96

-3.18%↓

JNJ

155.56

-1.06%↓

UNH

385.73

-1.37%↓

ABBV

185.44

-1.29%↓

ABT

133.82

-0.01%↓

Search

IQVIA Holdings Inc

Closed

SectorHealthcare

153.3 0.09

Overview

Share price change

24h

Current

Min

150.23

Max

156.38

Key metrics

By Trading Economics

Income

152M

437M

Sales

58M

4B

P/E

Sector Avg

20.491

54.379

EPS

3.12

Profit margin

11.041

Employees

88,000

EBITDA

165M

1B

Recommendations

By TipRanks

Recommendations

Buy

12 Months Forecast

+28.87% upside

Dividends

By Dow Jones

Next Earnings

21 Jul 2025

Market Stats

By TradingEconomics

Market Cap

-9.5B

27B

Previous open

153.21

Previous close

153.3

News Sentiment

By Acuity

10%

90%

4 / 382 Healthcare

Technical Score

By Trading Central

Confidence

Bullish Evidence

IQVIA Holdings Inc Chart

Past performance is not a reliable indicator of future results.

Related News

8 May 2025, 23:59 UTC

Top News
Earnings

Naver 1Q Net Slumps on Higher Costs

8 May 2025, 23:39 UTC

Earnings

OCBC 1Q Net Down on Lower Interest Income

8 May 2025, 23:01 UTC

Earnings

Macquarie Raises Dividend After 5.5% Rise in Annual Profit -- Update

8 May 2025, 22:52 UTC

Earnings

REA Expects Annual Listings Growth Despite April Decline

8 May 2025, 22:46 UTC

Earnings

Macquarie Raises Dividend After 5.5% Rise in Annual Profit

8 May 2025, 23:45 UTC

Market Talk

Global Equities Roundup: Market Talk

8 May 2025, 23:45 UTC

Market Talk

Nikkei May Rise as Tariffs Fears Ease -- Market Talk

8 May 2025, 23:41 UTC

Market Talk

Gold Rises on Possible Technical Recovery; Gains May be Capped by Risk-on Mood -- Market Talk

8 May 2025, 23:30 UTC

Earnings

Itau Unibanco 1Q Rev BRL45.02B >ITUB

8 May 2025, 23:29 UTC

Earnings

Itau Unibanco 1Q EPS BRL1.03 >ITUB

8 May 2025, 23:22 UTC

Earnings

Naver 1Q Net Profit Largely Met FactSet-Compiled Consensus

8 May 2025, 23:22 UTC

Earnings

Naver 1Q Net KRW423.70B Vs. Net KRW555.80B >035420.SE

8 May 2025, 23:21 UTC

Earnings

Naver 1Q Oper Pft KRW505.30B Vs. Pft KRW439.30B >035420.SE

8 May 2025, 23:21 UTC

Earnings

Naver 1Q Rev KRW2.787T Vs. KRW2.526T >035420.SE

8 May 2025, 23:17 UTC

Earnings

Oversea-Chinese Banking Corp. 1Q Net Interest Income S$2.35B Vs. S$2.44B >O39.SG

8 May 2025, 23:17 UTC

Earnings

Oversea-Chinese Banking Corp. 1Q Total Income S$3.66B Vs. S$3.63B >O39.SG

8 May 2025, 23:17 UTC

Earnings

Oversea-Chinese Banking Corp. 1Q Net S$1.88B Vs. Net S$1.98B >O39.SG

8 May 2025, 23:05 UTC

Market Talk

ANZ Could Cut Dividend by 10% From 2H -- Market Talk

8 May 2025, 23:05 UTC

Market Talk

Global Equities Roundup: Market Talk

8 May 2025, 23:01 UTC

Top News

With U.K. Deal, U.S. Signals That 10% Tariff on World Is New Baseline -- WSJ

8 May 2025, 22:28 UTC

Earnings

REA Expects FY 2025 Listings Growth of 1-2%

8 May 2025, 22:28 UTC

Earnings

REA Says April Listings Decline Reflects Year Ago Strength, Timing of Easter and Election

8 May 2025, 22:27 UTC

Earnings

REA Says April Sydney, Melbourne Listings Both Down 16% on Year

8 May 2025, 22:27 UTC

Earnings

REA Says April Residential Listings Fell by 11% on Year

8 May 2025, 22:26 UTC

Earnings

REA 3Q Operating Expenses A$176 Million, Up 12% on Year

8 May 2025, 22:26 UTC

Earnings

REA 3Q Free Cash Flow A$132 Million, Up 19% on Year

8 May 2025, 22:26 UTC

Earnings

REA 3Q Operating Ebitda A$199 Million, Up 12% on Year

8 May 2025, 22:26 UTC

Earnings

REA Nine-Months Free Cash Flow A$389 Million, Up 21% on Year

8 May 2025, 22:25 UTC

Earnings

REA Nine-Months Operating Expenses A$513 Million, Up 15% on Year

8 May 2025, 22:25 UTC

Earnings

REA Nine-Months Operating Ebitda A$734 Million, Up 19% on Year

Peer Comparison

Price change

IQVIA Holdings Inc Forecast

Price Target

By TipRanks

28.87% upside

12 Months Forecast

Average 197.56 USD  28.87%

High 270 USD

Low 160 USD

Based on 17 Wall Street analysts offering 12 month price targets forIQVIA Holdings Inc - Dist in the last 3 months.

Rating Consensus

By TipRanks

Buy

17 ratings

12

Buy

5

Hold

0

Sell

Technical Score

By Trading Central

150.68 / 155.07Support & Resistance

Short Term

Bullish Evidence

Intermediate Term

Neutral Evidence

Long Term

Bearish Evidence

Sentiment

By Acuity

4 / 382 Healthcare

News Sentiment

Very Strong Bullish Evidence

Volatility

Below average

News Volume (RCV)

Above average

Financials

Selling and administration expenses

Operating expenses

Pre-tax profit

Sales

Cost of sales

Gross profit on sales

Interest expense on debt

EBITDA

Operating profit

$

About IQVIA Holdings Inc

IQVIA Holdings Inc. engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions. The Technology & Analytics Solutions segment offers a range of cloud-based applications and related implementation services; real world solutions that enable life sciences and provider customers to generate and disseminate evidence, which informs health care decision making and improves patients' outcomes; and strategic and implementation consulting services, such as advanced analytics and commercial processes outsourcing services. This segment also provides country level performance metrics related to sales of pharmaceutical products, prescribing trends, medical treatment, and promotional activity across various channels, including retail, hospital, and mail order; and measurement of sales or prescribing activity at the regional, zip code, and individual prescriber level. The Research & Development Solutions segment offers project management and clinical monitoring; clinical trial support; strategic planning and design services; and patient and site centric solutions, as well as central laboratory, genomic, bioanalytical, ADME, discovery, and vaccine and biomarker laboratory services. The Contract Sales & Medical Solutions segment provides health care provider and patient engagement services, and scientific strategy and medical affairs services. It serves pharmaceutical, biotechnology, device and diagnostic, and consumer health companies. The company has a collaboration with argenx SE; and a strategic collaboration with NVIDIA Corporation. The company was formerly known as Quintiles IMS Holdings, Inc. and changed its name to IQVIA Holdings Inc. in November 2017. The company is headquartered in Durham, North Carolina.